Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.